Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]
Status:
Active, not recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
This study was conducted to evaluate the complete response rate of avelumab in patients with
NK / T-cell lymphoma besides relapsed or refractory stage lymphoma.